UmbREALung - A Retrospective and prospective, observational, real world multi-cohort study of patients with non-small cell lung cancer (NSCLC) initiating approved drugs developed by AZ or as part of an AZ alliance

Trial Identifier: D4191R00060
Sponsor: AstraZeneca
Start Date: December 2024
Primary Completion Date: June 2032
Study Completion Date: June 2032

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France AIX EN PROVENCE, France, 13100
France ANGERS, France
France AURILLAC, France, 15000
France AUXERRE, France
France AVIGNON, France
France BLOIS, France, 41016
France BORDEAUX, France, 33000
France BOURG EN BRESSE, France
France CARCASSONNE, France, 11010
France Chalon sur Saone, France, 71321
France Chambery, France, 73000
France CHATEAUROUX, France
France CRETEIL, France, 94000
France DIEPPE, France, 76202
France DINAN, France, 22100
France DREUX, France
France EPAGNY METZ TESSY, France
France Le COUDRAY, France, 28630
France LIMOGES, France
France Lyon, France, 69437
France MARSEILLE, France
France MEAUX, France, 77100
France METZ, France, 57000
France MULHOUSE, France, 68100
France NANCY, France, 54100
France NANTES, France, 44200
France NICE, France, 06000
France NIMES, France, 30029
France PERPIGNAN, France, 66000
France ST BRIEUC, France, 22000
France ST ETIENNE, France, 42100
France ST HERBLAIN, France, 44800
France SURESNES, France
France TOULOUSE, France, 31076
France TROYES, France, 10000
France VALENCIENNES, France, 59300
France VANNES, France, 56017
France VILLEFRANCHE SUR SAONE Cedex, France
France VILLEURBANNE, France, 69100